In Brief: Focal
This article was originally published in The Gray Sheet
Executive Summary
Focal: Inks collaborative product development agreement with Chiron and Ciba Pharmaceuticals under which Chiron and Ciba restenosis drug candidates will be combined with Focal's development-stage biodegradable gel drug delivery technology. Focal says the agreement will provide "research funding, milestone fees and future royalty payments on product sales." Focal's light-activated, adhering gel is designed to be deposited locally via a fiber-optic, double-balloon catheter that is under development. After placement, the drug combined with the gel would slowly release as the gel degrades, Focal explains...